Welcome to our dedicated page for Emergent Biosolutions news (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent Biosolutions stock.
Emergent BioSolutions Inc. (NYSE: EBS) regularly issues news and updates that reflect its focus on public health threats and pharmaceutical preparation manufacturing. Company announcements highlight developments across its commercial naloxone franchise, medical countermeasures portfolio, manufacturing network and financial performance, providing context for how Emergent pursues its stated mission to protect and save lives.
News items frequently cover product and regulatory milestones, such as U.S. Food and Drug Administration approvals and supplemental applications. Examples include FDA approval of over‑the‑counter NARCAN® Naloxone HCl Nasal Spray 4 mg and approval of a supplemental Biologics License Application for raxibacumab manufacturing at Emergent’s Winnipeg, Canada facility. Releases also describe new packaging options, such as the NARCAN® Nasal Spray carrying case designed to make naloxone easier to carry and more discreet.
Emergent’s news flow also features government contracts and contract modifications for medical countermeasures. Recent announcements describe delivery orders and options to supply BioThrax® (Anthrax Vaccine Adsorbed), ACAM2000® (Smallpox (Vaccinia) Vaccine, Live), CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), TEMBEXA® and BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to U.S. government agencies responsible for preparedness and response.
Investors and observers can also find financial and corporate updates, including quarterly earnings releases, segment performance commentary, debt prepayments under term loan facilities, and notices of presentations at healthcare conferences. Additional news addresses board‑level changes and corporate governance matters.
Other communications focus on public health initiatives and collaborations, such as support for opioid poisoning awareness observances, partnerships aimed at increasing workplace access to naloxone, and collaboration with PANTHER and Africa CDC on the MpOx Study in Africa. Together, these updates offer insight into how Emergent’s products, contracts, research collaborations and financial decisions relate to its role in addressing health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies.
Emergent BioSolutions reported exceptional financial results for Q4 and full year 2020, with total revenues of $583.0 million for Q4, up 62% year-on-year, and $1,555.4 million for the full year, a 41% increase. Net income for Q4 surged to $185.4 million, improving net income per diluted share to $3.44. The company reaffirmed its 2021 revenue forecast of $1,950 - $2,050 million, citing robust CDMO services and product sales growth, particularly in response to COVID-19. Notable initiatives included expanding manufacturing capacity and signing new agreements for drug product manufacturing.
Emergent BioSolutions (NYSE: EBS) will host a conference call on February 18, 2021 at 5:00 PM ET to discuss Q4 2020 financial results, recent business developments, and 2021 revenue guidance. Investors can access the call via phone at (855) 766-6521 (toll-free) or via webcast at this link. A replay will be available on the Emergent website post-call. The company aims to enhance public health and protect lives through its products and services.
Emergent BioSolutions and Humanigen have entered into a contract development and manufacturing (CDMO) agreement to accelerate production of lenzilumab, an antibody aimed at treating COVID-19 related cytokine storms. The deal leverages manufacturing capacity reserved by the U.S. government through the Department of Defense and aims for an emergency use authorization (EUA) in Q1 2021. Emergent's advanced facilities in Baltimore will support increased production, forming a key part of Humanigen's growth strategy.
Emergent BioSolutions (NYSE: EBS) announced participation in key investor conferences for Q1 2021. These include:
- 39th Annual J.P. Morgan Healthcare Conference from January 11-14, 2021, with a presentation on January 11 at 8:20 am EST.
- J.P. Morgan 2021 Global High Yield & Leveraged Finance Conference on March 1-3, 2021, with details to be updated on their website.
- Cowen 41st Annual Health Care Conference from March 1-4, 2021, also pending updates.
Webcasts will cover recent developments and financial results.
Emergent BioSolutions (EBS) and Mount Sinai Health System have initiated a clinical program to evaluate COVID-HIG for post-exposure prophylaxis against SARS-CoV-2. Two Phase 1 studies will assess safety and pharmacokinetics in healthy adults and adults with mild COVID-19. The U.S. Department of Defense has provided $34.6 million in funding, alongside a prior $14.5 million grant from HHS. The partnership aims to protect high-risk individuals, such as healthcare workers, by leveraging Mount Sinai's plasma collection capabilities, although COVID-HIG is not yet FDA-approved.
Emergent BioSolutions (EBS) reported strong Q3 2020 results with total revenues of $385.2 million, up 24% from Q3 2019. Year-to-date revenues reached $972.4 million, a 30% increase. Adjusted net income rose to $119.0 million, or $2.19 per diluted share in Q3. The company refined its 2020 financial forecast, projecting total revenues between $1.52 - $1.58 billion and adjusted net income between $375 - $405 million.
Despite strong performance, product sales declined 21% due to lower sales of travel health vaccines.
Emergent BioSolutions (EBS) will host a conference call on November 5, 2020, at 5:00 PM ET, to discuss Q3 2020 financial results, recent business developments, and revenue guidance for Q4 2020 and full year 2020. The call can be accessed via telephone or live webcast. Details including dial-in numbers and conference ID are provided in the release. The company aims to enhance life through specialty products and services, aspiring to protect or enhance 1 billion lives by 2030.
Emergent BioSolutions (NYSE:EBS) has initiated a Phase 3 clinical trial for its COVID-19 Human Immune Globulin (COVID-HIG) under the sponsorship of NIAID. This trial, named INSIGHT-013, aims to evaluate the safety and efficacy of COVID-HIG in hospitalized COVID-19 patients, with approximately 500 participants expected. COVID-HIG is intended to augment the natural antibody response to SARS-CoV-2 when combined with remdesivir. Emergent has secured $14.5 million in funding for COVID-HIG and is also exploring its use in high-risk populations.
Emergent BioSolutions (NYSE: EBS) announced a partnership with the Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and MAPDA to promote awareness of overdose reversal medicines on International Overdose Awareness Day, August 31, 2020. The collaboration will include special announcements and presentations aimed at emphasizing the importance of accessing life-saving medications. Doug White, SVP of Emergent, stressed the need for public awareness and access to these medicines to combat opioid overdoses. The initiative aligns with Emergent's mission to enhance public health and community safety.
Emergent BioSolutions (NYSE: EBS) announced the appointment of Marvin L. White as a Class II director on its board, effective October 1, 2020. Mr. White, who previously served on the board from 2010 to 2016, brings significant experience from the pharmaceutical and healthcare sectors. He has held leadership positions at Aptevo Therapeutics, St. Vincent Health, and Eli Lilly. His role on the board aims to enhance the company's growth strategy and increase shareholder value, as emphasized by executive chairman Fuad El-Hibri.
FAQ
What is the current stock price of Emergent Biosolutions (EBS)?
What is the market cap of Emergent Biosolutions (EBS)?
